The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 20, 2016

Filed:

Mar. 27, 2015
Applicants:

Norma A. Alcantar, Tampa, FL (US);

Rana Falahat, Tampa, FL (US);

Marzenna Wiranowska, Lutz, FL (US);

Ryan G. Toomey, Tampa, FL (US);

Inventors:

Norma A. Alcantar, Tampa, FL (US);

Rana Falahat, Tampa, FL (US);

Marzenna Wiranowska, Lutz, FL (US);

Ryan G. Toomey, Tampa, FL (US);

Assignee:

University of South Florida, Tampa, FL (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61K 9/127 (2006.01); A61K 31/337 (2006.01); A61K 47/36 (2006.01); A61K 38/17 (2006.01); A61K 9/06 (2006.01); A61K 47/24 (2006.01);
U.S. Cl.
CPC ...
A61K 9/127 (2013.01); A61K 9/06 (2013.01); A61K 9/1277 (2013.01); A61K 31/337 (2013.01); A61K 38/1767 (2013.01); A61K 47/24 (2013.01); A61K 47/36 (2013.01);
Abstract

Specific drug delivery to tumor cells without affecting normal cells is a major challenge in cancer treatment. The present invention incorporates embedding nonionic surfactant vesicles (niosomes) containing an anti-cancer therapeutic agent with chlorotoxin into a thermosensitive chitosan hydrogel network. Chitosan has mucoadhesive property which can be used in the targeting of the tumor cells with the mucin over expression. Chlorotoxin is a 36 amino acid peptide obtained fromscorpion venom which binds preferentially to tumor cells of neuroectodermal origin but not to normal cells. The incorporation of chlorotoxin along with niosomes in the chitosan hydrogel is used as the second targeting strategy to further improve the specific delivery of drugs to tumor cells such as glioma.


Find Patent Forward Citations

Loading…